Cereblon contributes to cardiac dysfunction by degrading Cav1.2α.
Nammi ParkJubert MarquezTrong Kha PhamTae Hee KoJae Boum YoumMin KimSeung Hak ChoiJiyoung MoonJessa FloresKyung Soo KoByoung Doo RheeIppei ShimizuTohru MinaminoJae Du HaJong Yeon HwangSeung Joo YangChul-Seung ParkHyoung Kyu KimJin HanPublished in: European heart journal (2022)
Cereblon selectively degrades Cav1.2α, which in turn facilitates cardiac dysfunction. A targeted approach or an efficient method of reducing CRBN levels could serve as a promising strategy for HFrEF therapeutics.